# Metformin Treatment on Cognitive Impairment of Schizophrenia

> **NCT05838573** · PHASE3 · RECRUITING · sponsor: **Central South University** · enrollment: 120 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Metformin treatment
- **DRUG:** Placebo treatment
- **OTHER:** Baseline assessments
- **OTHER:** Volunteer assessments

## Key facts

- **NCT ID:** NCT05838573
- **Lead sponsor:** Central South University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-08
- **Primary completion:** 2026-12-12
- **Final completion:** 2027-06-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-12-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05838573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05838573, "Metformin Treatment on Cognitive Impairment of Schizophrenia". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT05838573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*